Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) have received a consensus rating of "Moderate Buy" from the five research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $7.00.

A number of research analysts have recently weighed in on the stock. HC Wainwright restated a "buy" rating and set a $16.00 price target on shares of Esperion Therapeutics in a report on Tuesday, June 17th. Needham & Company LLC cut their price target on shares of Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, The Goldman Sachs Group cut their price target on shares of Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating on the stock in a report on Thursday, April 17th.

Esperion Therapeutics Trading Up 1.8%

ESPR stock traded up $0.02 during midday trading on Friday, reaching $1.17. The company had a trading volume of 2,321,688 shares, compared to its average volume of 4,826,056. Esperion Therapeutics has a 1 year low of $0.69 and a 1 year high of $3.94. The company has a market capitalization of $232.09 million, a P/E ratio of -1.46 and a beta of 0.70. The company has a 50 day moving average of $0.99 and a two-hundred day moving average of $1.46.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.03). The company had revenue of $65.00 million during the quarter, compared to analysts' expectations of $54.97 million. Esperion Therapeutics had a negative return on equity of 0.91% and a negative net margin of 59.03%. On average, sell-side analysts anticipate that Esperion Therapeutics will post -0.29 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ESPR. Meridian Wealth Management LLC bought a new position in Esperion Therapeutics in the 1st quarter worth $29,000. Cibc World Markets Corp bought a new position in Esperion Therapeutics in the 4th quarter worth $39,000. Synergy Asset Management LLC raised its holdings in Esperion Therapeutics by 3,496.3% in the 1st quarter. Synergy Asset Management LLC now owns 31,000 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 30,138 shares during the period. Private Advisor Group LLC raised its holdings in Esperion Therapeutics by 33.2% in the 1st quarter. Private Advisor Group LLC now owns 40,106 shares of the biopharmaceutical company's stock worth $58,000 after acquiring an additional 10,000 shares during the period. Finally, Crestline Management LP acquired a new stake in Esperion Therapeutics in the 4th quarter worth $63,000. Institutional investors own 47.39% of the company's stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.